Syndecan-1 in Liver Diseases

Eszter Regős, Katalin Karászi, Andrea Reszegi, András Kiss, Zsuzsa Schaff, Kornélia Baghy, Ilona Kovalszky

Research output: Contribution to journalArticle

1 Citation (Scopus)


Liver diseases such as liver cirrhosis, primary and metastatic liver cancers are still a major medical challenge. Syndecan-1 is one of the most important proteoglycans in the liver. Syndecan-1 is normally expressed on the surfaces of hepatocytes and cholangiocytes. Due to liver diseases the amount of syndecan-1 increases in the liver. Despite the emerging data of the biological function of syndecan-1, the clinical usefulness of this proteoglycan is still unknown. In our study we correlated syndecan-1 expression to clinico-pathological data. We found that syndecan-1 proved to be a good marker for hepatitis C virus based hepatocellular carcinoma and increased with liver dysfunction.

Original languageEnglish
Pages (from-to)813-819
Number of pages7
JournalPathology and Oncology Research
Issue number2
Publication statusPublished - Apr 1 2020


  • Cirrhosis
  • Hepatocellular carcinoma
  • Liver
  • Metastasis
  • Syndecan-1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Syndecan-1 in Liver Diseases'. Together they form a unique fingerprint.

  • Cite this

    Regős, E., Karászi, K., Reszegi, A., Kiss, A., Schaff, Z., Baghy, K., & Kovalszky, I. (2020). Syndecan-1 in Liver Diseases. Pathology and Oncology Research, 26(2), 813-819.